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questions in 
reasons such 
analysis.  
Results: To a t, 
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't Veer et al., 2
fact the result t of 
patients used for gene selection. Many equally predictive lists could have been 
produced from e analysis.  Three main properties of the data explain this 
sensitivity: (a orrelated with survival; (b) the differences between 
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over different
properties is d
 
INTRODUC
Several attem
Tibshirani, 20
Rosenwald et
2003; Sorlie 
profiling. Sor
clustering, to assign breast carcinoma tissues to one of five different subtypes, each 
with a distinctive expression profile. Robustness of these survival related subclasses 
was demonstrated(Sorlie et al., 2003) by applying the same analysis procedure to two 
independent breast carcinoma data sets(van 't Veer et al., 2002; West et al., 2001). 
van't Veer et al.(van 't Veer et al., 2002) applied a supervised approach to identify a 
gene-expression signature, based on 70 genes, capable of predicting a short interval to 
development of distant metastases. First, they randomly selected a set of 78 patients, a 
training set, which was used to measure the correlation between each gene's 
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Predicting the metastatic potential of primary malignant tissues has 
 on choice of therapy.  Several microarray studies yielded gene sets 
sion profiles successfully predicted survival(Ramaswamy et al., 2003; 
001; van 't Veer et al., 2002). Nevertheless, the overlap between these 
lmost zero. Such small overlaps were observed also in other complex 
 for the differences had evoked a wide interest. One of the main open 
this context is whether the disparity can be attributed only to trivial 
as different technologies, different patients and different types of 
nswer this question we concentrated on one single breast cancer datase
it by one single method, the one which was used by van’t Veer et al.(van
002) to produce a set of outcome predictive genes. We showed that in 
ing set of genes is not unique; it is strongly influenced by the subse
 the sam
) many genes are c
ons are small; (c) the correlations fluctuate strongly when measured 
 subsets of patients. A possible biological explanation for these 
iscussed. 
 
TION 
pts were made to predict survival of cancer patients in general (Bair and 
04; Beer et al., 2002; Khan et al., 2001; Nguyen and Rocke, 2002; 
 al., 2002), and of breast cancer patients in particular(Ramaswamy et al., 
et al., 2001; van 't Veer et al., 2002) on the basis of gene expression 
lie et al.(Sorlie et al., 2001) used an unsupervised approach, hierarchical 
expression an
and the 70 m
between patie
the test set to
al., 2002) pro
295 tumor sp
identified a se
of 17 metastases associated genes were tested on a large diverse set of primary solid 
tumors, and w
prognosis. 
The predictiv
survival relat
common. Onl
al., 2001) and
genes were shared between the sets of Sorlie et al. (Sorlie et al., 2001) and 
Ramaswamy 
cancer but characterizes other human disease datasets such as schizophrenia(Miklos 
and Maleszka
In this work we explore this surprising phenomenon, and suggest new explanations 
for the lack of
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including axi
ratios were m
cRNA from a
genes(Hughes
 
Preprocessin
The full expr
columns (sam ria, based on the entire set of 117 
samples, yielding 5852 genes that exhibited two-fold change of expression with a p-
value less tha  samples (van't Veer et al applied the same filtering 
criteria on 98  
genes). We di
than 20% mi r 
analysis). Lik nts 
free of BRCA1/2 germ line mutations. 
 
Correlation analysis 
For each gene we test the null hypothesis that its gene expression profile is 
uncorrelated with the survival vector (over all 96 samples). We randomly permuted 
the survival vector (105 times) and calculated the correlation of the expression of each 
gene with the randomized survival vector. The p-value is the fraction of times one 
gets an absolute correlation larger or equal to the absolute correlation of the un-
d disease outcome. The genes were ranked according to this correlation, 
ost correlated genes were used to construct a classifier discriminating 
nts with good and poor prognosis. The remaining 19 patients served as 
 validate their prognosis classifier. A follow-up study (van de Vijver et 
ved the efficiency of this classifier as survival predictor on a large set of 
ecimens. In a third study, Ramaswamy et al.(Ramaswamy et al., 2003) 
t of 128 genes separating metastases from primary tumors. A refined set 
ere found to distinguish successfully patients with good versus poor 
e success of these studies was frustrated by the fact that the sets of 
ed genes identified by these three studies had only a few genes in 
y 17 genes appeared in both the list of 456 genes of Sorlie et al.(Sorlie et 
 the 231 genes of van't Veer et al.(van 't Veer et al., 2002) ; merely 2 
et al.(Ramaswamy et al., 2003) Such disparity is not limited to breast 
, 2004).  
 agreement between the sets of genes. 
S AND METHODS 
et 
 't Veer et al., 2002) contain gene expression profiles of primary breast 
96 sporadic young patients with grade T1/T2 tumors less than 5cm in 
no lymph node metastas
radical mastectomy 
llary lymph node dissection followed by radiotherapy. Hybridization 
easured with respect to a reference made by pooling equal amounts of 
ll the sporadic carcinomas, on microarrays containing 25,000 human 
 et al., 2001). 
g of data 
ession matrix of van't Veer et al had 24481 rows (genes) and 117 
ples). We applied filtering crite
n 0.01 in 5 or more
 samples, while discarding the test set of 19 samples, yielding 5000
scarded from the set a single sample (sample 54) which contained more 
ssing values (van't Veer et al decided to include this patient in thei
e van't Veer et al, we also based our analysis on 96 'sporadic' patie
permuted data
Discovery Ra
yielded a list o ams 
of the correlat l and with a 
randomly permuted survival vector, are shown in Fig 1A.   
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To examine h
the 70 most 
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samples into a poor prognosis set of 45 samples, and a good prognosis set of 51. We 
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Measuring th
We assumed that the degree of the polynomial fit for the average STD curve (see Fig. 
5) is the degre lynomial fit to the STD curve of each individual gene.  
Using this assumption, we found the polynomial fit to the STD curve of each gene in 
the data, and used it to estimate their STD values in a sample size of 77.   
 
 
RESULTS 
 
. Correction for multiple comparisons was performed using the False 
te (FDR) method. Bounding the expected false discovery rate by 10% 
f 1234 genes for which the null hypothesis can be rejected. Histogr
on (measured for 5852 genes) with the true survivai
data into ten different divisions of 77/19 
ow different experiments of 77 samples, influence the composition of 
correlated genes with survival, we used the bootstrapping method 
993). Bootstrapping is a computer simulation enabling to overcome 
fects. It assumes that the sample is a good approximation of the 
y generating a large number of new samples from the original sample 
 estimate the statistics parameters of the population. To keep the 
ognosis ratio of the original training set (33/44) we divided the 96 
etitions a random set of 33 samples from the poor pro
 prognosis. We repeated this procedure ten times and found the top 70 
 'training set' composition. 
e STD of a gene based on a sample-size of 77 
e of the po
 
Fig. 1. A. Th
(projection on
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normalized su
pole while B
correlation w
characterized 
their relative 
other. All oth
illustrate how all blue 
are far). The genes create an elongated structure at an angle <π/2 with s, implying that 
a large number of genes exhibit non-vanishing correlations with survival.  
 
 
 
Many genes a
This lack of 
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to genuine di
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al., 2002). Th
outcome is r
representing d 0 
representing 
expression ve
vector (s) and
We chose to
characterized 
The 5852 gen
equator. If su
lies on the pl
correlation of
geometrical m he expression vectors of very many genes 
(1234 - at an FDR of 10%, see Methods) are related to survival. 
According to our model, if the experiment is repeated on a different group of patients 
(with the same clinical characteristics), the overall appearance of the new "globe" will 
be quite similar, but the positions of individual genes will swarm around. This 
swarming suffices to change drastically the relative ranking of the genes on the basis 
of their correlation with survival. 
 
e histogram of the genes' correlation with the real survival vector 
to the vertical s axis - red curve), and with a random permutation of the 
r (blue curve). B. Globe of genes in the ``world" spanned by the 
rvival (s), BUB1 (b) and ESR1 (e). The survival is located at the north-
UB1 (chosen from a large cluster of genes characterized by negative 
ith survival) and ESR1 (chosen from a large cluster of genes 
by positive correlation with survival) are on the sphere's surface and 
locations are determined by their angles with survival and with each 
er (normalized) genes are represented by spots whose size and color 
lose the gene is to the surface (large red spots are close and sm c
re related to survival 
agreement can be attributed to different chips, different methods of 
ation, mRNA extraction and analysis of the data and, most importantly - 
fferences between the patients (tumor grade, stage etc). To eliminate 
of variation, we focused on data from a single experiment(van 't Veer et 
e data consist of 96 samples and 5852 genes (see Methods). Disease 
epresented by a survival vector s, of 96 binary components, with 1 
good prognosis (metastasis free time interval >5 years), an
poor prognosis (<5 years). The projection of the 96-dimensional 
ctor of each gene onto a 3-dimensional space (spanned by the survival 
 the expression vectors of ESR1 (e) and BUB1 (b)) is shown in Fig. 1B. 
 use ESR1 and BUB1 as representative genes of two large clusters 
by positive and negative correlation with survival, respectively.  
es comprise an oblate spheroid shaped cloud, tilted with respect to the 
rvival is replaced by a random binary vector, the oblate spheroid cloud 
ane of the equator. Since the vertical component of each gene is the 
 its expression with survival (see Fig. 1A), this difference is a striking 
anifestation of the fact that t
 
erage performance of series of classifiers generated by consecutive sets Fig. 2. The av
of 70 genes. The fluctuating curves present the number of errors produced by the 
classifiers res
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the rank of th
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errors.  
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as low as thos h highest correlation to 
survival). Of 
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Many sets of 
This data-set
correlated wit
and third, the 
set (shown lat
to others in predicting disease outcome. To test this hypothesis, we selected the same 
77 patients (out of 78, see Methods, and van 't Veer et al., 2002) and ranked all genes 
according to their correlation with survival. We used the 5852 genes to build a series 
of classifiers (following the method used by van 't Veer et al.), based on consecutive 
groups of 70 genes. For each classifier we measured the training and the test error, 
and found seven other sets of 70 genes, producing classifiers with the same prognostic 
capabilities as those based on the top 70. The genes of some of these seven classifiers 
appeared way down in the correlation-ranked list; the 70 genes of the first classifier 
ulting from one particular selection of training and test sets (upper – 
 out of 77 samples; lower – test errors, out of 19. The x-axis represents 
e genes in the classifiers. The average over 1000 partitions is plotted as 
 two grey areas are the 95% confidence intervals of the training and test 
e of the first classifier (based on the 70 genes wit
the 1000 partitions, for ~28% no such classifier was found, whereas for 
ound. Note that more than 70% of the training sets produce at least one 
 the same performance as the top 70 genes; the expected number of such 
round 4. 
70 genes can be used to predict survival 
 is characterized by three main properties: first, many genes are 
h survival. Second, the differences between these correlations are small 
correlation-based rankings of the genes depend strongly on the training 
er). These properties may indicate that the top 70 genes are not superior 
are ranked be
281-350, clas
701-770.  The
shown in Fig ation), and the 
corresponding Kaplan-Meier plots are shown below (see Fig. 3).  
 
tween 71 to 140, classifier2: 141-210, classifier3: 211-280, classifier4: 
sifier4: 351-420, classifier5: 421-490,  classifier6: 561-630, classifier7: 
 location of these 7 sets on the globe and their predicting performance is 
9 and Fig. 11, respectively (see supplementary inform. 
 
 Fig. 3. Kaplan-Meier analysis of van't Veer et al.'s classifier and of the seven 
alternative cl
describe the 
classified as 
poor prognosi
 
 
To ensure tha
and test sets s
for 1000 diff
samples). Eac
of classifiers 
measured for each classifier. Note, that when repeating this procedure for a 
randomized survival vector, the training error curve fluctuates around 37.5 mistakes 
(50% rate of errors) while the test error fluctuates around 9.5 mistakes, independent 
on the genes' rank. The results shown in Fig. 2 imply that indeed, for each of the 
training sets, classifiers based on very low ranked genes are capable of predicting 
survival with quality similar to the high ranking ones. To give a quantitative meaning 
to this claim we generated the histogram presented in the inset of Fig. 2, which shows 
that more than 70% of the 1000 training sets produced at least one classifier with the 
assifiers as obtained from classifying all 96 samples. Upper curves 
probability of remaining free of metastasis in the group of samples 
having good prognosis signature, while the lower curves describe the 
s group. 
t the aforementioned phenomenon is not unique to the specific training 
elected by van 't Veer et al., we repeated the procedure described above 
erent compositions of training sets (of 77 samples) and test sets (19 
h training set was used to rank the genes, and for each case the sequence 
described above was constructed, and the training and test errors were 
same (or bette
number of suc
(a) the list of 
the training se
with a fixed training set, one could have easily singled out a different group of 70 
much lower r
ranked genes. 
Our results im
groups of 70 
the main can
selected from ted by the 
following list
We list sever
parentheses), 
Negative corr
supports tumo
2000), CKS2 
al., 2001) and
regulation or 
(92)(Varamba
Positive corre
growth, affec
inhibition of 
functions lik
apoptotic(Li e
correlation of
enhance anti-t
in all normal 
induces apopt
(255) is high
(285) is also p ince it is a target of ER 
(Bertucci et al., 2000; Guerin et al., 1990) which is positively correlated with 
outcome. None of the genes listed above is ranked among the top 70! 
Note that as opposed to claims made in (Gruvberger et al., 2003), the success of the 
classifier is not due to the correlation of outcome to ER status. Creating a data set 
which lacks this correlation, our 7 classifiers, as well as van't Veer et al.'s, kept their 
prognostic capabilities (see supplementary information). 
 
r) performance as the one based on its own top 70 genes. The average 
h classifiers is 4. The surprising summary of these observations is that 
"top 70 genes" of highest correlation with survival depends strongly on 
t of (77) patients on which the correlation was measured and (b) even 
anked genes with as good a prognostic performance as that of the top 
ply that although the top 70 genes may provide good prediction, other 
genes may do the same. Hence, these 70 genes cannot be considered as 
didates for targeting anti-cancer treatment. Such candidates should be 
 the much longer list of genes related to survival, as demonstra
 of cancer-related genes, present in the 7 classifiers mentioned above. 
al of these genes, and indicate next to each one its correlation rank (in 
measured on the training set selected by van 't Veer et al.  
elation with survival: IL-6 (rank=502) is anti-apoptotic, and therefore 
r survival (Lotem et al., 2003); CDC25B (402) (Nilsson and Hoffmann, 
(297) (Urbanowicz-Kachnowicz et al., 1999), CDC2 (229) (Winters et 
 CDC20 (341) (Singhal et al., 2003) are known to function in cell cycle 
DNA replication; oncogenes NRAS (260) (Boon et al., 2003), EZH2 
lly et al., 2002).  
lation with survival may be caused by some indirect relation to tumor 
ting survival through indirect mechanisms like immunity, apoptosis or 
oncogenes. Examples: BIN1/AMPH2 (477) by binding to MYC 
e a tumor suppressor(Sakamuro et al., 1996); BIK (342) is pro-
t al., 2003) via binding to BCL2 (1106) (Li et al., 2003). The positive 
 FLT3 (220) is due to its strong effect on dendritic cells and T-cells to 
umor immunity (Ciavarra et al., 2003). BRAK (237) is highly expressed 
tissues but low in malignant cells (Hromas et al., 1999); IGFBP4 (225) 
osis(Byron and Yee, 2003; Zhou et al., 2003). Expression of GATA3 
ly correlated with ER status (Bertucci et al., 2000). Similarly, MYB 
ositively correlated with breast cancer outcome s
 
 of top 70 genes, identified in 10 randomly chosen training sets of N=77 
g bootstrapping – see Methods). Each row represents a gene and each 
ining-set. The genes were ordered according to their correlation rank in 
ng set (leftm
Fig. 4. 10 sets
patients (usin
column – a tra
the first traini ost column). For each training set, the 70 top-ranked genes 
are colored black. The genes that were top ranked in one training-set can have a much 
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training set.. 
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fluctuations o
composition o
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the overall go
that have the highest correlation with survival. The significant variation of the 
membership of the top 70 genes is clearly shown in Fig. 10 of the Supplementary 
Information. Note that every pair of these training sets has at least 58 samples in 
common, which significantly reduces the fluctuations of r and variation of the genes' 
ranks. In spite of this, the average overlap between two such gene groups is only 
33.7/70. To better estimate the "true" fluctuations of r for independent subgroups of 
77 we used bootstrapping (Tibshirani, 1993), drawing subgroups from the 96 samples 
with repeats (see Methods). This reduces the expected overlap of two top-70-gene 
en another training-set is used. The two rightmost columns (columns 11 
 the those of the 70 genes published by van 't Veer et al.  and the 128 
ng in (Ramaswamy et al., 2003) that are among the top 1000 of our first 
 may fluctuate 
re the correlation r of a gene's expression with survival on the basis of a 
patients drawn at random from a larger group with similar clinical 
. If a different set of N is drawn, the correlation will be different. If 
al fluctuations of r are sizeable, they may change the ranking of a gene 
ne sample to a much lower rank in another; the smaller N, the larger the 
f r. In order to estimate the effect of these fluctuations on the 
f gene lists such as those of (van 't Veer et al., 2002), we repeatedly 
ent subgroups of 77 samples out of the 96 (in each group we maintained 
od/poor prognosis ratio) and for each subgroup identified the 70 genes 
lists to 12.2/7
10 subgroups.
are likely to b
from a clinica ld different lists of "top 70 genes" with respect 
to correlation with survival. 
 
 
0. Fig. 4 shows how large are the variation of gene rank, measured for 
  Genes whose correlation with survival ranked high over one subgroup 
ecome low ranked in another. Hence different sets of 77 patients, drawn 
ly similar pool, will yiel
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deviation (STD) of the correlation. We repeated this procedure 5 times (each time 
creating a different set of subgroups), to obtain 
rd deviation of gene’s correlation w
(y-axis) as a function of sample size K (x-axis).The curve is the 
t to the results obtained for K between 2 to 48. This curve was used to 
e STD to larger values of K (The values extrapolated to K=77 were used 
e error-bars presented in Fig. 6).  
e correlation fluctuations 
udy how the fluctuations of the correlation with survival vary with the 
, we created nK non-overlapping subgroups of size K from the 96 
ples. We calculated the correlation of each gene g with survival, 
r each subgroup, and from these nK values we estimated the standard-
 0 to 96 (see Fig. 5). As shown in 
σ g (K), the average STD, for each of 
the 5852 genes, for K ranging from 2 to 48 (the maximal K allowing for non-
overlapping subgroups). Finally, we extrapolated the correlation noise (estimated by 
<σ >, the STD averaged over the genes), from K =
Fig. 5 the correlation noise decreases as the samples-size increases. For sample-size of 
77 (the size of the training set), the expected average noise is ~0.1, whereas the 
significant genes found by van't Veer et al and by our study show correlation between 
0.3 to 0.5. In ll signal to noise ratio, the phenomenon shown in Fig. 4 
is not surprising.  
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Fig. 6. Correlation of genes with survival vs their ranks. The correlation of each gene 
(y-axis) was m
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Focusing on 
ranked genes 
among the 70 top ranked genes. Conversely, genes ranked among the top 70 can 
easily fluctuate to much lower ranks. The relatively low signal to noise ratio explains 
the phenomenon demonstrated in Fig. 4. In order to estimate the actual probability of 
each gene to be included in a list of  top 70, we generated, at random, 10000 training 
sets, each of 77 samples. For each such training set we identified the top 70 genes. 
The fraction of times (among 10000) that each gene appeared in the top 70 is shown 
in Fig. 7. 
 
 
 
easured based on the 96 samples, and the genes were ordered according 
ation magnitude (X axis). The error-bars represent the noise (STD) of a 
 sample-size 77 (see Methods). 
sample-size K=77 (see Fig. 6), one can see that even relatively low 
(around 1000), may have a non negligible probability to be included 
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Taking into account the correlation noise, we defined an alternative gene score 
(instead of correlation coefficient), by calculating its probability to have a correlation 
above a given threshold for a given sample size (see Supplementary Information). Fig. 
8 presents the probability of genes to have correlation higher than a given threshold 
(y-axis) calculated on the basis of the noise derived for samples size of 77. The x-axis 
represents the genes' ranks according to their correlation coefficient with all 96 
samples. 
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e basis of their correlation with outcome, as measured over the 77 
e particular (randomly chosen) training set. 
 
 
Fig. 8. Probability (y-axis) of genes to have correlation higher than a given threshold, 
calculated on the basis of noise derived for a training set of 77 samples. The x-axis 
represents the
curve correspo
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between lists of survival related genes generated from the same data set, the 
disagreement between lists obtained from different data sets is not surprising. A 
possible biological explanation for this may be the individual variations and 
heterogeneities associated with markers for outcome, even within a clinically 
homogenous group of patients. 
Perhaps one has to divide the patients into smaller subgroups(Sorlie et al., 2003) on 
the basis of some yet unknown attribute and for each subgroup of tumors look for it's 
much sought "primary master genes" that control metastatic potential. The 
 gene ranks according to their correlation with all 96 samples. The left 
nds to threshold of 0.4 and the right curve to threshold 0.1.  
 
e investigated a single breast cancer data set (van 't Veer et al., 2002) in 
explain the inconsistency between lists of survival related genes derived 
t experiments. While no single gene has a very high correlation with 
many the correlation has intermediate values (Fig. 1). The differences 
 correlation values are small, and the relative ranking of genes on the 
lation with survival changes drastically when a different training-set is 
arge fluctuations in gene rank indicate that the identities of the top 70 
 are not robust, and hence will not be reproduced in a different 
 spite of this sensitivity, the predictive power of several sets of genes is 
he main lesson is that whenever any arbitrary decision (e.g. choice of 
est set) is taken throughout analysis of the data, one has to generate a 
e of the different ways in which this arbitrary decision could be taken, 
a statistical analysis of the results obtained over this ensemble. High 
the results to the arbitrary decisions may indicate that the conclusions, 
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